SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-027568
Filing Date
2022-10-04
Accepted
2022-10-04 16:49:57
Documents
14
Period of Report
2022-10-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41089
2 ex99-1.htm EX-99.1 13914
3 ex99-1_001.jpg GRAPHIC 10880
  Complete submission text file 0001493152-22-027568.txt   247279

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gtbp-20221004.xsd EX-101.SCH 3236
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gtbp-20221004_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gtbp-20221004_pre.xml EX-101.PRE 22365
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3590
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 221292538
SIC: 2834 Pharmaceutical Preparations